Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | CCR8 | P51685 | 1/20 | 0.40 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29638019 | 1.00 | PKM (0.44) | PKMNPSR1ALDH1A1MEN1KMT2A | |
| SCHEMBL29638000 | 1.00 | PKM (0.44) | PKMNPSR1ALDH1A1MEN1KMT2A | |
| SCHEMBL23026354 | 0.89 | PKM (0.46) | PKMNPSR1ALDH1A1MEN1KMT2A | |
| SCHEMBL22130764 | 0.87 | SLC6A4 (0.43) | NPSR1ALDH1A1KMT2AL3MBTL1HSD17B10 | |
| SCHEMBL16765639 | 0.87 | SLC6A4 (0.43) | NPSR1ALDH1A1KMT2AL3MBTL1HSD17B10 | |
| SCHEMBL16765638 | 0.87 | SLC6A4 (0.43) | NPSR1ALDH1A1KMT2AL3MBTL1HSD17B10 | |
| SCHEMBL11149702 | 0.80 | HTR2C (0.48) | PKMNPSR1ALDH1A1MEN1KMT2A | |
| SCHEMBL25925867 | 0.77 | ALDH1A1 (0.46) | PKMNPSR1ALDH1A1MEN1KMT2A | |
| SCHEMBL31432992 | 0.77 | ALDH1A1 (0.48) | PKMNPSR1ALDH1A1MEN1KMT2A | |
| SCHEMBL9749200 | 0.77 | ALDH1A1 (0.48) | PKMNPSR1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10822352-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20190211033-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | US | disclosed |
| EP-2516430-B1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2014-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10822352-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | PKM 3975/4885NPSR1 1700/4885ALDH1A1 1682/4885 |
| US-20190211033-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, F12, F3 | PKM 3975/4885NPSR1 1700/4885ALDH1A1 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.